These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 38384463)

  • 1. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
    Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U
    Front Immunol; 2024; 15():1323198. PubMed ID: 38384463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.
    Poyia F; Neophytou CM; Christodoulou MI; Papageorgis P
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
    Graziano V; Dannhorn A; Hulme H; Williamson K; Buckley H; Karim SA; Wilson M; Lee SY; Kaistha BP; Islam S; Thaventhiran JED; Richards FM; Goodwin R; Brais R; Morton JP; Dovedi SJ; Schuller AG; Eyles J; Jodrell DI
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
    Stouten I; van Montfoort N; Hawinkels LJAC
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.
    Chibaya L; DeMarco KD; Lusi CF; Kane GI; Brassil ML; Parikh CN; Murphy KC; Chowdhury SR; Li J; Ma B; Naylor TE; Cerrutti J; Mori H; Diaz-Infante M; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    Sci Transl Med; 2024 Aug; 16(762):eadj9366. PubMed ID: 39196958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.
    Hartupee C; Nagalo BM; Chabu CY; Tesfay MZ; Coleman-Barnett J; West JT; Moaven O
    Front Immunol; 2024; 15():1287459. PubMed ID: 38361931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma.
    Sperb N; Tsesmelis M; Wirth T
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma.
    Li X; Hou W; Xiao C; Yang H; Zhao C; Cao D
    Cell Oncol (Dordr); 2024 Oct; 47(5):1561-1578. PubMed ID: 39008192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
    Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
    Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
    Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
    Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
    Merali N; Jessel MD; Arbe-Barnes EH; Ruby Lee WY; Gismondi M; Chouari T; O'Brien JW; Patel B; Osei-Bordom D; Rockall TA; Sivakumar S; Annels N; Frampton AE
    HPB (Oxford); 2024 Jul; 26(7):873-894. PubMed ID: 38729813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers.
    Taherian M; Wang H; Wang H
    Cells; 2022 Sep; 11(19):. PubMed ID: 36231030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.
    Muller M; Haghnejad V; Schaefer M; Gauchotte G; Caron B; Peyrin-Biroulet L; Bronowicki JP; Neuzillet C; Lopez A
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.
    Jin Y; Christenson ES; Zheng L; Li K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):945-958. PubMed ID: 38690749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.